Related Experiment Video
Updated: Jan 27, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer]
A Kretschmer1, D Tilki2,3
1Urologische Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians Universität München, München, Deutschland.
Abstract:
Until 2018, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC/M0CRPC) did not have a generally acknowledged standard of care therapy. As a result, these patients were often managed in a nonstandardized individual fashion and comparative analyses were lacking. In the current narrative review, we give an overview on the respective entities of nmCRPC and summarize novel treatment options that arose from the publication of the results of the SPARTAN and PROSPER trials and their subanalyses. We critically address the role that novel imaging modalities, namely 68Ga-PSMA-PET/CT (68Ga prostate-specific membrane antigen positron emission tomography/computed tomography) will play in the diagnosis of nmCRPC and raise the question whether incidence rates of true nmCRPC will significantly decline in the nearer future.
Insights
Until 2018, nonmetastatic castration-resistant prostate cancer (nmCRPC) lacked standard care. Novel treatments and advanced imaging like 68Ga-PSMA-PET/CT are changing nmCRPC diagnosis and management.
Area of Science:
- Oncology
- Radiology
Background:
- Nonmetastatic castration-resistant prostate cancer (nmCRPC) previously lacked a standard of care.
- Patient management was individualized and lacked comparative analysis.
Purpose of the Study:
- To review nmCRPC and novel therapeutic options.
- To discuss the impact of advanced imaging on nmCRPC diagnosis.
Main Methods:
- Narrative review of existing literature.
- Analysis of SPARTAN and PROSPER trial data.
- Discussion of 68Ga-PSMA-PET/CT imaging.
Main Results:
- Novel treatments have emerged for nmCRPC.
- 68Ga-PSMA-PET/CT may redefine nmCRPC diagnosis.
- The incidence of true nmCRPC may decrease with new imaging.
Conclusions:
- New therapeutic options improve nmCRPC management.
- Advanced imaging like 68Ga-PSMA-PET/CT is crucial for accurate nmCRPC diagnosis.
- Future incidence of nmCRPC may be impacted by diagnostic advancements.
Related Concept Videos
Treatment Resistant Cancers
Modern Molecular Taxonomy
Resistivity
Resistance
Bioavailability: Influencing Factors
The Influence of Affect on Cognition

